^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LZTS1 (Leucine Zipper Tumor Suppressor 1)

    i
    Other names: LZTS1, Leucine Zipper Tumor Suppressor 1, FEZ1, F37/Esophageal Cancer-Related Gene-Coding Leucine-Zipper Motif, Leucine Zipper, Putative Tumor Suppressor 1, Leucine Zipper Putative Tumor Suppressor 1, Fez1, F37
    2ms
    Prognostic value of brown adipocyte-related genes in colorectal cancer: a multi-omics and Mendelian randomization study. (PubMed, Discov Oncol)
    ADD2, PDE1B, LZTS1, and PCSK5 were identified as prognostic genes. A prognostic model related to BARGs in CRC was established, offering fresh perspectives on the prognostic treatment of CRC.
    Journal
    |
    LZTS1 (Leucine Zipper Tumor Suppressor 1)
    4ms
    Development of multiple cell death pattern features to predict prognosis and drug sensitivity in gastric adenocarcinoma. (PubMed, Transl Oncol)
    This study presents a robust prognostic model based on RCD-related genes, offering insights into immune response and drug sensitivity for personalized STAD treatment.
    Journal
    |
    SERPINE1 (Serpin Family E Member 1) • LZTS1 (Leucine Zipper Tumor Suppressor 1)
    |
    temozolomide
    5ms
    Immunogenic cell death-related macrophage gene model for prognostic prediction in glioblastoma. (PubMed, Discov Oncol)
    Tumor microenvironment profiling has revealed that the high-risk patients display elevated stromal and immune scores, alongside reduced tumor purity, indicative of a densely infiltrated, macrophage-rich microenvironment. By elucidating the interaction between ICD and macrophage biology, this study establishes a robust prognostic model that surpasses traditional clinical parameters, offering insights into tumor microenvironment immunity and therapeutic vulnerabilities in GBM.
    Journal
    |
    G0S2 (G0/G1 Switch 2) • LZTS1 (Leucine Zipper Tumor Suppressor 1) • NEUROD1 (Neuronal Differentiation 1)
    11ms
    Natural resistance to cancers in long-lived mammals: genomic mechanisms and experimental evidence to explain Peto's paradox. (PubMed, Sci China Life Sci)
    Of them, the YAP1 gene, harboring the A214S mutation, was identified as a key gene that upregulated tumor suppression genes by localizing to the cytoplasm, which might prohibit cancer development in the large and long-lived cetaceans. These findings provide novel insights into the molecular mechanisms underlying natural cancer resistance in long-lived mammals and the biological basis of Peto's paradox.
    Journal
    |
    YAP1 (Yes associated protein 1) • LZTS1 (Leucine Zipper Tumor Suppressor 1)
    over1year
    Unveiling the oncogenic role of LZTS1 in colorectal cancer. (PubMed, J Cell Mol Med)
    Furthermore, depletion of LZTS1 repressed the proliferation and migration rate of CRC cells. Thus, this study indicates that LZTS1 plays an oncogenic role in colorectal carcinogenesis.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • CDH1 (Cadherin 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • CDH2 (Cadherin 2) • LZTS1 (Leucine Zipper Tumor Suppressor 1)
    almost2years
    MOLECULAR PROFILING OF ALL IN PEDIATRIC PATIENTS TREATED AT SOLCA, GUAYAQUIL. EVALUATION OF PROGNOSTIC VALUE. PRELIMINARY REPORT. (EHA 2024)
    This is a preliminary report of the results of NGS analysis of a group of pediatric patients that will allow riskstratification and will provide recommendations of diverse therapeutical approaches within the concept ofpersonalized medicine. The 198 genes panel is ample and identified mutations present in a cluster of 8 genes in the entire set of cases(46/46). We will correlate the obtained mutational profile with response to treatment and relapse considering eternalfactors as nutritional status and access to medical services and medication.
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NOTCH1 (Notch 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • WT1 (WT1 Transcription Factor) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • CSF1R (Colony stimulating factor 1 receptor) • FOXP1 (Forkhead Box P1) • CALR (Calreticulin) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • LZTS1 (Leucine Zipper Tumor Suppressor 1) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor) • PDGFC (Platelet Derived Growth Factor C)
    |
    CRLF2 rearrangement • BCL11B mutation
    |
    FusionPlex™ Pan-Heme panel
    almost2years
    Influence of clinical and genetic factors on propofol dose requirements: A genome-wide association study. (PubMed, Anesthesiology)
    In this first GWAS exploring propofol requirements, we discovered novel genetic associations suggesting new biologically relevant pathways for propofol and general anesthesia. The roles of the gene products of ROBO3/FEZ1, NALCN and KCNJ2 in propofol anesthesia warrant further studies.
    Journal
    |
    LZTS1 (Leucine Zipper Tumor Suppressor 1) • ROBO3 (Roundabout Guidance Receptor 3) • NALCN (Sodium Leak Channel, Non-Selective)
    2years
    Unlocking the potential of Escherichia coli K-12: A novel approach for malignancy reduction in colorectal cancer through gene expression modulation. (PubMed, Gene)
    Also, our findings demonstrated that E. coli K-12 may regulate the expression of genes linked to a high death rate. In summary, the results of this study suggest that E. coli K-12 can be regarded as a significant probiotic with the potential to mitigate the risk of CRC development.
    Journal
    |
    KLF4 (Kruppel-like factor 4) • LZTS1 (Leucine Zipper Tumor Suppressor 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    over2years
    LncRNA LZTS1-AS1 induces proliferation, metastasis and inhibits autophagy of pancreatic cancer cells through the miR-532 /TWIST1 signaling pathway. (PubMed, Cancer Cell Int)
    Our results suggest that lncRNA LZTS1-AS1 acts as an oncogene to promote the metastasis of PANC and inhibit autophagy, and its mechanism may be to regulate TWIST1 through sponge miR-532. This study provides novel biomarkers and therapeutic targets for PANC.
    Journal
    |
    TWIST1 (Twist Family BHLH Transcription Factor 1) • LZTS1 (Leucine Zipper Tumor Suppressor 1) • MIR532 (MicroRNA 532)
    over3years
    MiR-762 regulates the activation of PI3K/AKT and Hippo pathways involved in the development of gastric cancer by targeting LZTS1. (PubMed, Am J Transl Res)
    MiR-762 activates PI3K/AKT and suppresses Hippo pathways to boost GC proliferation and invasion by targeting LZTS1.
    Journal
    |
    LZTS1 (Leucine Zipper Tumor Suppressor 1)
    over3years
    Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer. (PubMed, Pathol Res Pract)
    For the first time, we evaluated the relationship between LZTS1 expression and chemotherapy sensitivity using the Collagen gel droplet drug sensitivity test(CD-DST) in primary cell culture of breast cancer. LZTS1 may play an important role in improving the sensitivity of paclitaxel-based breast cancer chemotherapy.
    Journal
    |
    LZTS1 (Leucine Zipper Tumor Suppressor 1)
    |
    LZTS1 overexpression
    |
    paclitaxel